pravastatin has been researched along with Cancer of Prostate in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ravnskov, U | 1 |
| Freedland, SJ; Goldberg, KC; Hamilton, RJ; Platz, EA | 1 |
| D'Avolio, LW; Farwell, WR; Gaziano, JM; Lawler, EV; Scranton, RE | 1 |
| Freeman, MR; Solomon, KR | 1 |
| Adamovich, E; Allen, ZA; Butler, EG; Butler, WM; Galbreath, RW; Merrick, GS; Moyad, MA; Wallner, KE | 1 |
| Abbas, T; Dutta, A; Sivaprasad, U | 1 |
| Ito, MK; Lin, JC | 1 |
1 review(s) available for pravastatin and Cancer of Prostate
| Article | Year |
|---|---|
The complex interplay between cholesterol and prostate malignancy.
Topics: Androgens; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors | 2011 |
6 other study(ies) available for pravastatin and Cancer of Prostate
| Article | Year |
|---|---|
Re: The association between statins and cancer incidence in a veterans population.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Bias; Colorectal Neoplasms; Confounding Factors, Epidemiologic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Lung Neoplasms; Male; Neoplasms; Pravastatin; Prostatic Neoplasms; Simvastatin; United States; Veterans | 2008 |
The influence of statin medications on prostate-specific antigen levels.
Topics: Aged; Atorvastatin; Biomarkers, Tumor; Cholesterol, HDL; Cholesterol, LDL; Early Diagnosis; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Linear Models; Longitudinal Studies; Lovastatin; Male; Middle Aged; Multivariate Analysis; Pravastatin; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Risk Assessment; Simvastatin; Veterans | 2008 |
Statins and prostate cancer diagnosis and grade in a veterans population.
Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Biomarkers, Tumor; Cholesterol; Confounding Factors, Epidemiologic; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Indoles; Lipids; Lovastatin; Male; Middle Aged; Multivariate Analysis; New England; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Risk Assessment; Severity of Illness Index; Simvastatin; Veterans | 2011 |
Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.
Topics: Aged; Atorvastatin; Biopsy; Brachytherapy; Cause of Death; Chemotherapy, Adjuvant; Chi-Square Distribution; Disease-Free Survival; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; Neoplasm Staging; Pravastatin; Proportional Hazards Models; Prostatic Neoplasms; Pyrroles; Retrospective Studies; Simvastatin; Survival Analysis | 2006 |
Differential efficacy of 3-hydroxy-3-methylglutaryl CoA reductase inhibitors on the cell cycle of prostate cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase 2; Fatty Acids, Monounsaturated; Fluvastatin; G1 Phase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Male; p21-Activated Kinases; Phosphorylation; Pravastatin; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Simvastatin | 2006 |
Chronic creatine kinase elevation not associated with HMG-CoA reductase inhibitor treatment.
Topics: Biomarkers, Tumor; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pravastatin; Prostatic Neoplasms; Renal Insufficiency | 1999 |